A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

NCT05572515 PHASE3 ACTIVE_NOT_RECRUITING

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	614
Start date	Wed Mar 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Aug 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

• Teclistamab
• Pomalidomide
• Bortezomib
• Dexamethasone
• Carfilzomib

Countries

Italy, Japan, Malaysia, Poland, Denmark, Netherlands, Belgium, Sweden, Czechia, Portugal, United States, France, Greece, Austria, Israel, Canada, Brazil, Spain, United Kingdom, Germany, Australia, China, Turkey (Türkiye), India